The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
Inclusion Criteria: * Healthy male subjects aged 20-45 years at screening * Body weight over 50 kg, inclusive, and within 20% of ideal body weight Exclusion Criteria: * Has a present illness or medical history of hepatic, renal, respiratory, cardiovascular disease, blood tumor, mental disorder, and endocrinologic disorder, especially diabetes mellitus * Has a sign or symptom or history related to an acute or chronic pancreatitis * Has a known allergy or hypersensitivity to exenatide or other drugs such as aspirin, antibiotics, and so on * Has ever been exposed to exenatide * Shows SBP \>= 150 mmHg or \<= 90 mmHg or DBP \>= 100 mmHg or \<= 50 mmHg * Has a presence or history of drug abuse * Uses any prescription drug, herbal medicine within 2 weeks or OTC drugs or vitamin within 1 week prior to study drug administration * Has been participated in other clinical trial within 2 months * Has experience of a blood donation during 2 months or a blood transfusion during 1 month prior to study drug administration * Heavy smoker more than 10 cigarettes/day within 3 months prior to screening * Continuous drinker (over 21 units/week, 1 unit = 10 g of pure alcohol) or subject who can't quit drinking nor smoking during clinical trial period * Subjects not eligible at the discretion of investigators